title: Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
abstract: A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I non-small cell lung cancer?'. Altogether over 318 papers were found, of which 18 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Stereotactic ablative radiotherapy (SABR) and sublobar resection (SLR) offer clear survival benefit in the treatment of early-stage non-small-cell lung cancer (NSCLC) in high-risk patients unsuitable for lobectomy and SABR has shown good results in medically operable patients. No randomized data are available comparing SLR and SABR, and therefore, data from prospective studies were compared. Overall survival at 1 year was similar between patients treated with SABR and SLR (81-85.7 vs 92%); however, overall 3-year survival was higher following SLR (87.1 vs 45.1-57.1%). There was no statistically significant difference in local recurrence in patients treated with SABR compared with SLR (3.5-14.5 vs 4.8-20%). Both treatment modalities are associated with complications. Fatigue (31-32.6%), pneumonitis (2.1-12.5%) and chest wall pain (3.1-12%) were common following SABR; however, serious grade 3 and 4 toxicity were rare. Morbidity following SLR was reported between 7.3 and 33.7%. Thirty-day mortality following SABR was 0%, while predicted 30-day mortality following a lung resection, using the thoracoscore predictive model ranges between 1 and 2.6%. Treatment for early-stage NSCLC should be tailored to individual patients. SABR is an acceptable alternative to SLR in high-risk patients but comparative data are required.
authors.affiliation: Royal Oldham Hospital, Oldham, Lancashire, UK.
authors.forename: Sarah
authors.initials: S
authors.lastname: Mahmood
authors.forename: Haris
authors.initials: H
authors.lastname: Bilal
authors.forename: Corinne
authors.initials: C
authors.lastname: Faivre-Finn
authors.forename: Rajesh
authors.initials: R
authors.lastname: Shah
mesh_terms: D019985:Benchmarking; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D018579:Patient Selection; D011013:Pneumonectomy / Q000009:adverse effects / Q000401:mortality; D016634:Radiosurgery / Q000009:adverse effects / Q000401:mortality; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
keywords: Non-small-cell lung cancer; Stereotactic ablative radiotherapy; Sublobar resection; Survival
references.citation: Interact Cardiovasc Thorac Surg. 2003 Dec;2(4):405-9
references.pmid: 17670084
references.citation: J Thorac Cardiovasc Surg. 2012 Feb;143(2):428-36
references.pmid: 22169443
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4833-9
references.pmid: 17050868
references.citation: J Thorac Cardiovasc Surg. 2005 Feb;129(2):261-7
references.pmid: 15678034
references.citation: Ann Thorac Surg. 2006 Feb;81(2):434-8; discussion 438-9
references.pmid: 16427827
references.citation: J Clin Oncol. 2010 Feb 20;28(6):928-35
references.pmid: 20065181
references.citation: JAMA. 2010 Mar 17;303(11):1070-6
references.pmid: 20233825
references.citation: J Thorac Oncol. 2011 Dec;6(12):2036-43
references.pmid: 21892102
references.citation: Lung Cancer. 2010 Apr;68(1):72-7
references.pmid: 19556022
references.citation: Ann Thorac Surg. 2004 Jul;78(1):228-33; discussion 228-33
references.pmid: 15223434
references.citation: Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82
references.pmid: 19251380
references.citation: J Am Coll Surg. 2010 Jul;211(1):68-72
references.pmid: 20610251
references.citation: Cancer. 2004 Oct 1;101(7):1623-31
references.pmid: 15378503
references.citation: J Thorac Cardiovasc Surg. 2011 Nov;142(5):1143-51
references.pmid: 21872277
references.citation: J Thorac Cardiovasc Surg. 2003 Apr;125(4):924-8
references.pmid: 12698157
references.citation: J Thorac Oncol. 2006 Oct;1(8):802-9
references.pmid: 17409963
references.citation: Cancer. 2010 Jan 15;116(2):406-14
references.pmid: 19950125
references.citation: J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93
references.pmid: 15632829
references.citation: Ann Surg Oncol. 2012 Feb;19(2):661-8
references.pmid: 21769464
references.citation: Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92
references.pmid: 18164849
references.citation: Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
references.pmid: 7677489